News Headlines Article

FDA puts brakes on Geron blood treatment
San Francisco Business Times

Geron Corp.’s imetelstat — an experimental blood treatment on which the company is staking a turnaround — was placed in a full clinical hold Wednesday by the Food and Drug Administration. The stock of the Menlo Park company (NASDAQ: GERN) fell 68 percent Wednesday from Tuesday’s close, from $4.52 to as low as $1.39, but gained more than 5.6 percent Thursday to close at $1.79 per share.